J Rheum Dis.  2020 Oct;27(4):218-232. 10.4078/jrd.2020.27.4.218.

Recommendations for the Management of Patients With Systemic Rheumatic Diseases During the Coronavirus Disease Pandemic

• Seo MR
• Kim JW
• Park EJ
• Jung SM
• Sung YK
• Kim H
• Kim G
• Kim HS
• Lee MS
• Lee J
• Hur J
• Chin BS
• Eom JS
• Baek HJ
• The Korean College of Rheumatology Working Group

• KMID: 2506975
• DOI: http://doi.org/10.4078/jrd.2020.27.4.218

Abstract

Patients with systemic rheumatic diseases (SRD) are vulnerable for coronavirus disease (COVID-19). The Korean College of Rheumatology recognized the urgent need to develop recommendations for rheumatologists and other physicians to manage patients with SRD during the COVID-19 pandemic. The working group was organized and was responsible for selecting key health questions, searching and reviewing the available literature, and formulating statements. The appropriateness of the statements was evaluated by voting panels using the modified Delphi method. Four general principles and thirteen individual recommendations were finalized through expert consensus based on the available evidence. The recommendations included preventive measures against COVID-19, medicinal treatment for stable or active SRD patients without COVID-19, medicinal treatment for SRD patients with COVID-19, and patient evaluation and monitoring. Medicinal treatments were categorized according to the status with respect to both COVID-19 and SRD. These recommendations should serve as a reference for individualized treatment for patients with SRD. As new evidence is emerging, an immediate update will be required.

Keyword

Coronavirus; SARS-CoV-2; Rheumatic diseases; Recommendations; Treatment

Reference

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. 2020; A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382:727–33. DOI: 10.1056/NEJMoa2001017. PMID: 31978945. PMCID: PMC7092803.

2. World Health Organization. c2020. WHO announces COVID-19 outbreak a pandemic [Internet]. World Health Organization;Geneva: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic. cited 2020 Mar 12.

3. World Health Organization. c2020. Coronavirus disease (COVID-19) pandemic [Internet]. World Health Organization;Geneva: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. cited 2020 May 17.

4. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. 2020; The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 35:e61. DOI: 10.3346/jkms.2020.35.e61. PMID: 32030925. PMCID: PMC7008073.

5. Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, et al. 2020; Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 109:102442. DOI: 10.1016/j.jaut.2020.102442. PMID: 32253068. PMCID: PMC7127009.

6. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. CORRONA Investigators. 2011; High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 70:785–91. DOI: 10.1136/ard.2010.128637. PMID: 21288960.

7. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. 2007; Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 66:308–12. DOI: 10.1136/ard.2006.057265. PMID: 16984941. PMCID: PMC1856002.

8. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. 2008; Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 59:1074–81. DOI: 10.1002/art.23913. PMID: 18668604.

9. Jani M, Barton A, Hyrich K. 2019; Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Curr Opin Rheumatol. 31:285–92. DOI: 10.1097/BOR.0000000000000598. PMID: 30789850. PMCID: PMC6443047.

10. Youssef J, Novosad SA, Winthrop KL. 2016; Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 42:157–76. ix–x. DOI: 10.1016/j.rdc.2015.08.004. PMID: 26611557. PMCID: PMC4751577.

11. Gabriel SE, Michaud K. 2009; Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 11:229. DOI: 10.1186/ar2669. PMID: 19519924. PMCID: PMC2714099.

12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. 2020; Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395:1054–62. DOI: 10.1016/S0140-6736(20)30566-3. PMID: 32171076. PMCID: PMC7270627.

13. Ruan Q, Yang K, Wang W, Jiang L, Song J. 2020; Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46:846–8. DOI: 10.1007/s00134-020-05991-x. PMID: 32125452.

14. Centre for Evidence-Based Medicine. c2016. OCEBM levels of evidence [Internet]. Centre for Evidence-Based Medicine;Oxford: https://www.cebm.net/2016/2005/ocebm-levels-of-evidence/. cited 2020 Apr 23.

15. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. c2001. The RAND/UCLA appropriateness method user's manual [Internet]. RAND Corporation;Santa Monica (CA): http://www.rand.org/pubs/monograph_reports/MR1269.html. cited 2020 Apr 23.

16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. 2020; Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–20. DOI: 10.1056/NEJMoa2002032. PMID: 32109013. PMCID: PMC7092819.

17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. 2020; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. DOI: 10.1016/S0140-6736(20)30183-5. PMID: 31986264. PMCID: PMC7159299.

18. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. 2020; Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323:1061–9. DOI: 10.1001/jama.2020.1585. PMID: 32031570. PMCID: PMC7042881.

19. Wu Z, McGoogan JM. 2020; Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 323:1239–1242. DOI: 10.1001/jama.2020.2648. PMID: 32091533.

20. European League Against Rheumatism. c2020. EULAR calls on governments in Europe to recognize the most vulnerable during COVID-19 [Internet]. European League Against Rheumatism;Kilchberg: https://www.eular.org/call_on_governments.cfm. cited 2020 Apr 23.

21. Centers for Disease Control and Prevention. c2020. People who are at increased risk for severe illness [Internet]. Centers for Disease Control and Prevention;Atlanta (GA): https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. cited 2020 Jun 25.

22. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. 2020; COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 201:1380–8. DOI: 10.1164/rccm.202002-0445OC. PMID: 32275452. PMCID: PMC7258639.

23. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. 2005; Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 32:1473–80. PMID: 16078322.

24. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. 2007; Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 46:327–34. DOI: 10.1093/rheumatology/kel236. PMID: 16880188.

25. Listing J, Gerhold K, Zink A. 2013; The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 52:53–61. DOI: 10.1093/rheumatology/kes305. PMID: 23192911.

26. Singh JA. 2016; Infections with biologics in rheumatoid arthritis and related conditions: a scoping review of serious or hospitalized infections in observational studies. Curr Rheumatol Rep. 18:61. DOI: 10.1007/s11926-016-0609-5. PMID: 27613285.

27. Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, et al. 2015; Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 67:1671–8. DOI: 10.1002/acr.22628. PMID: 26018115.

28. Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. 2019; A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 58:1755–66. DOI: 10.1093/rheumatology/kez087. PMID: 30982883.

29. The Korean Society of Infectious Diseases. c2020. Korean Society of Infectious Diseases recommendations for COVID-19 [Internet]. The Korean Society of Infectious Diseases;Seoul: http://www.ksid.or.kr/rang_board/list.html?num=3684&code=ncov_guide_do. cited 2020 May 28.

30. World Health Organization. c2020. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020 [Internet]. World Health Organization;Geneva: https://apps.who.int/iris/handle/10665/331329. cited 2020 Apr 23.

31. European Centre for Disease Prevention and Control. c2020. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020 [Internet]. European Centre for Disease Prevention and Control;Solna: https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov. cited 2020 May 29.

32. Centers for Disease Control and Prevention. c2020. Overview of testing for SARS-CoV-2 (COVID-19) [Internet]. Centers for Disease Control and Prevention;Atlanta (GA): https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC_AA_refVal=https%2013A%2012F%2012Fwww.cdc.gov%2012Fcoronavirus%2012F2019-ncov%2012Fclinical-criteria.html. cited 2020 Jul 17.

33. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. COVID-19 Global Rheumatology Alliance Steering Committee. 2020; Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2:e250–3. DOI: 10.1016/S2665-9913(20)30095-3. PMID: 32309814. PMCID: PMC7162647.

34. Misra DP, Agarwal V, Gasparyan AY, Zimba O. 2020; Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 39:2055–62. DOI: 10.1007/s10067-020-05073-9. PMID: 32277367. PMCID: PMC7145936.

35. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. 2020; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 79:685–99. DOI: 10.1136/annrheumdis-2019-216655. PMID: 31969328.

36. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2017; 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 76:978–91. DOI: 10.1136/annrheumdis-2016-210770. PMID: 28087505.

37. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. 2018; Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 77:3–17. DOI: 10.1136/annrheumdis-2017-211734. PMID: 28684559. PMCID: PMC5867399.

38. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019; 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 78:736–45. DOI: 10.1136/annrheumdis-2019-215089. PMID: 30926722.

39. World Health Organization. c2020. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020 [Internet]. World Health Organization;Geneva: https://apps.who.int/iris/handle/10665/331446. cited 2020 Apr 23.

40. National Health Service. c2020. Coronavirus guidance for clinicians and NHS managers [Internet]. National Health Service;Leeds: https://www.england.nhs.uk/coronavirus/. cited 2020 May 18.

41. Centers for Disease Control and Prevention. c2020. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [Internet]. Centers for Disease Control and Prevention;Atlanta (GA): https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-manage-ment-patients.html. cited 2020 Apr 23.

42. National Institutes of Health. c2020. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. National Institutes of Health;Bethesda (MD): https://covid19treatmentguidelines.nih.gov/. cited 2020 Apr 23.

43. World Health Organization. c2020. Clinical management of COVID-19: interim guidance, 27 May 2020 [Internet]. World Health Organization;Geneva: https://apps.who.int/iris/handle/10665/332196. cited 2020 May 28. DOI: 10.15557/PiMR.2020.0004.

44. World Health Organization. c2020. Interim recommendations on obligatory hand hygiene against transmission of COVID-19 [Internet]. World Health Organization;Geneva: https://www.who.int/publications/m/item/interim-recommendationsonobligatory-hand-hygiene-against-transmission-of-covid-19. cited 2020 Apr 23.

45. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. 2011; Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011:CD006207. DOI: 10.1002/14651858.CD006207.pub4. PMID: 21735402.

46. Ferner RE. c2020. Hand disinfectant and COVID-19 [Internet]. Centre for Evidence-Based Medicine;Oxford: https://www.cebm.net/covid-19/hand-disinfectant-and-covid-19/. cited 2020 Apr 23.

47. Jefferson T, Jones M, Al Ansari LA, Bawazeer G, Beller E, Clark J, et al. 2020; Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - face masks, eye protection and person distancing: systematic review and meta-analysis. medRxiv. DOI:10.1101/2020.03.30. 20047217. DOI: 10.1101/2020.03.30.20047217. PMID: 32496473.

48. Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. 2020; Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med. 8:434–6. DOI: 10.1016/S2213-2600(20)30134-X. PMID: 32203710. PMCID: PMC7118603.

49. Bae S, Kim MC, Kim JY, Cha HH, Lim JS, Jung J, et al. 2020; Effectiveness of surgical and cotton masks in blocking SARS-CoV-2: a controlled comparison in 4 patients. Ann Intern Med. 173:W22–3. DOI: 10.7326/M20-1342. PMID: 32251511. PMCID: PMC7153751.

50. Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau BJP, et al. 2020; Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 26:676–80. DOI: 10.1038/s41591-020-0843-2. PMID: 32371934. PMCID: PMC7252509.

51. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen H, et al. 2020; Face masks against COVID-19: an evidence review. Preprints. DOI:10.20944/preprints 202004.0203.v1. DOI: 10.20944/preprints202004.0203.v2.

52. Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L. 2020; Face masks for the public during the covid-19 crisis. BMJ. 369:m1435. DOI: 10.1136/bmj.m1435. PMID: 32273267.

53. Mahtani KR, Heneghan C, Aronson JK. c2020. What is the evidence for social distancing during global pandemics? ? [Internet]. Centre for Evidence-Based Medicine;Oxford: https://www.cebm.net/covid-19/what-is-the-evidence-for-social-distancing-during-global-pandemics/. cited 2020 Apr 23.

54. Choi S, Ki M. 2020; Estimating the reproductive number and the outbreak size of COVID-19 in Korea. Epidemiol Health. 42:e2020011. DOI: 10.4178/epih.e2020011. PMID: 32164053. PMCID: PMC7285447.

55. Korea Centers for Disease Control and Prevention. c2020. Preventive measures againt COVID-19 [Internet]. Korea Centers for Disease Control and Prevention;Seoul: http://ncov.mohw.go.kr/baroView4.do?brdId=4&brdGubun=44. cited 2020 Apr 23.

56. Korea Centers for Disease Control and Prevention. c2020. Social distancing [Internet]. Korea Centers for Disease Control and Prevention;Seoul: http://ncov.mohw.go.kr/guidelineList.do?brdId=6&brdGubun=61&dataGubun=611. cited 2020 Apr 23.

57. World Health Organization. c2020. Coronavirus disease (COVID-19) advice for the public [Internet]. World Health Organization;Geneva: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. cited 2020 Apr 23.

58. Centers for Disease Control and Prevention. c2020. How to protect yourself & others [Internet]. Centers for Disease Control and Prevention;Atlanta (GA): https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html. cited 2020 Apr 23.

59. National Health Service. c2020. Social distancing: what you need to do [Internet]. National Health Service;Leeds: https://www.nhs.uk/conditions/coronavirus-covid-19/staying-at-home-to-avoid-getting-coronavirus/staying-at-home-and-away-from-other-people/. cited 2020 May 28.

60. Sveaas SH, Smedslund G, Hagen KB, Dagfinrud H. 2017; Effect of cardiorespiratory and strength exercises on disease activity in patients with inflammatory rheumatic diseases: a systematic review and meta-analysis. Br J Sports Med. 51:1065–72. DOI: 10.1136/bjsports-2016-097149. PMID: 28455366.

61. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. 2017; EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 76:17–28. DOI: 10.1136/annrheumdis-2016-209775. PMID: 27697765.

62. Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, et al. 2018; 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 77:1251–60. DOI: 10.1136/annrheumdis-2018-213585. PMID: 29997112.

63. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine. 2011; American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 43:1334–59. DOI: 10.1249/MSS.0b013e318213fefb. PMID: 21694556.

64. Ahmadinejad Z, Alijani N, Mansori S, Ziaee V. 2014; Common sports-related infections: a review on clinical pictures, management and time to return to sports. Asian J Sports Med. 5:1–9. DOI: 10.5812/asjsm.34174. PMID: 24868426. PMCID: PMC4009082.

65. Halabchi F, Ahmadinejad Z, Selk-Ghaffari M. COVID-19 epidemic: exercise or not to exercise; that is the question! Asian J Sports Med 2020;11:e102630. DOI: 10.5812/asjsm.102630.

66. World Health Organization. c2020. Q&A: be active during COVID-19 [Internet]. World Health Organization;Geneva: https://www.who.int/news-room/q-a-detail/be-active-during-covid-19. cited 2020 Apr 23.

67. Hartmann-Boyce J, Lindson N. c2020. Smoking in acute respiratory infections [Internet]. Centre for Evidence- Based Medicine;Oxford: https://www.cebm.net/covid-19/smoking-in-acute-respiratory-infections/. cited 2020 Apr 23.

68. World Health Organization. c2020. Tobacco and waterpipe use increases the risk of COVID-19 [Internet]. World Health Organization;Geneva: http://www.emro.who.int/tfi/know-the-truth/tobaccoand-waterpipe-users-are-at-increasedrisk-of-covid19-infection.html. cited 2020 Apr 23.

69. Vardavas CI, Nikitara K. 2020; COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 18:20. DOI: 10.18332/tid/119324. PMID: 32206052. PMCID: PMC7083240.

70. Berlin I, Thomas D, Le Faou AL, Cornuz J. 2020; COVID-19 and smoking. Nicotine Tob Res. 22:1650–2. DOI: 10.1093/ntr/ntaa059. PMID: 32242236. PMCID: PMC7184428.

71. Freund KM, Belanger AJ, D'Agostino RB, Kannel WB. 1993; The health risks of smoking. The Framingham study: 34 years of follow-up. Ann Epidemiol. 3:417–24. DOI: 10.1016/1047-2797(93)90070-K. PMID: 8275219.

72. Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. 2001; Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol. 30:540–6. DOI: 10.1093/ije/30.3.540. PMID: 11416080.

73. Komiyama M, Hasegawa K. 2020; Smoking cessation as a public health measure to limit the coronavirus disease 2019 pandemic. Eur Cardiol. 15:e16. DOI: 10.15420/ecr.2020.11. PMID: 32373189. PMCID: PMC7199122.

74. Sopori M. 2002; Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2:372–7. DOI: 10.1038/nri803. PMID: 12033743.

75. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. 2010; Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 69:70–81. DOI: 10.1136/ard.2008.096487. PMID: 19174392.

76. Formica MK, Palmer JR, Rosenberg L, McAlindon TE. 2003; Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol. 30:1222–6. PMID: 12784393.

77. Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. 2015; Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 72:634–9. DOI: 10.1016/j.jaad.2014.12.025. PMID: 25648824.

78. Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. 2012; Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 148:317–22. DOI: 10.1001/archdermatol.2011.342. PMID: 22105815. PMCID: PMC3309110.

79. Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, et al. 2019; 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 22:340–56. DOI: 10.1111/1756-185X.13510. PMID: 30816645.

80. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. 2020; Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 323:2085–6. DOI: 10.1001/jama.2020.6266. PMID: 32293646. PMCID: PMC7160748.

81. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. 2020; Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 26:1324–6. DOI: 10.3201/eid2606.200299. PMID: 32160148. PMCID: PMC7258479.

82. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. 2020; Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 395:507–13. DOI: 10.1016/S0140-6736(20)30211-7. PMID: 32007143. PMCID: PMC7135076.

83. Cox MJ, Loman N, Bogaert D, O'Grady J. 2020; Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 1:e11. DOI: 10.1016/S2666-5247(20)30009-4. PMID: 32835323. PMCID: PMC7195315.

84. Arokiaraj MC. c2020. Correlation of influenza vaccination and influenza incidence on COVID-19 severity [Internet]. Social Science Research Network (SSRN);Rochester (NY): https://papers.ssrn.com/sol3/Papers.cfm?abstract_id=3572814. cited 2020 Apr 23. DOI: 10.2139/ssrn.3572814.

85. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2020; 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 79:39–52. DOI: 10.1136/annrheumdis-2019-215882. PMID: 31413005.

86. O'Mahony R, Richards A, Deighton C, Scott D. 2010; Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 69:1823–6. DOI: 10.1136/ard.2008.105577. PMID: 19224904.

87. Galvao TF, Zimmermann IR, da Mota LM, Silva MT, Pereira MG. 2016; Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 35:1659–68. DOI: 10.1007/s10067-016-3285-y. PMID: 27107756.

88. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. 1993; Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med. 95:258–64. DOI: 10.1016/0002-9343(93)90277-V. PMID: 8368224.

89. Joseph RM, Hunter AL, Ray DW, Dixon WG. 2016; Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 46:133–41. DOI: 10.1016/j.semarthrit.2016.03.001. PMID: 27105755. PMCID: PMC4987145.

90. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. 2007; EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 66:1560–7. DOI: 10.1136/ard.2007.072157. PMID: 17660219. PMCID: PMC2095301.

91. Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. 2019; Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 8:786. DOI: 10.3390/jcm8060786. PMID: 31163625. PMCID: PMC6617416.

92. Day M. 2020; Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 368:m1086. DOI: 10.1136/bmj.m1086. PMID: 32184201.

93. National Institute for Health and Care Excellence. c2020. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders [Internet]. National Institute for Health and Care Excellence;London: https://www.nice.org.uk/guidance/ng167. cited 2020 Apr 23.

94. Torjesen I. 2020; Covid-19: NICE advises against using NSAIDs for fever in patients with suspected cases. BMJ. 369:m1409. DOI: 10.1136/bmj.m1409. PMID: 32253225.

95. Little P. 2020; Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 368:m1185. DOI: 10.1136/bmj.m1185. PMID: 32220865.

96. Torjesen I. 2020; Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ. 369:m1555. DOI: 10.1136/bmj.m1555. PMID: 32303505.

97. World Health Organization. c2020. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 [Internet]. World Health Organization;Geneva: https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19. cited 2020 Apr 23. DOI: 10.15557/PiMR.2020.0022.

98. EMA advice on the use of NSAIDs for Covid-19. Drug Ther Bull 2020;58:69. DOI: 10.1136/dtb.2020.000021. PMID: 32234728.

99. Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M. 2020; Apr. 22. Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID). Ann Rheum Dis. [Epub]. DOI:10.1136/annrheumdis-2020-217598. DOI: 10.1136/annrheumdis-2020-217598. PMID: 32321720.

100. Chen D, Li H, Xie J, Zhan Z, Liang L, Yang X. 2017; Herpes zoster in patients with systemic lupus erythematosus: clinical features, complications and risk factors. Exp Ther Med. 14:6222–8. DOI: 10.3892/etm.2017.5297. PMID: 29285180. PMCID: PMC5740583.

101. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ, et al. Korean Society of Critical Care Medicine H1N1 Collaborative. 2011; Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 183:1207–14. DOI: 10.1164/rccm.201101-0110OC. PMID: 21471084.

102. Hui DS. 2018; Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 197:700–1. DOI: 10.1164/rccm.201712-2371ED. PMID: 29227752.

103. Russell CD, Millar JE, Baillie JK. 2020; Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 395:473–5. DOI: 10.1016/S0140-6736(20)30317-2.

104. Singh AK, Majumdar S, Singh R, Misra A. 2020; Role of corticosteroid in the management of COVID-19: a systemic review and a clinician's perspective. Diabetes Metab Syndr. 14:971–8. DOI: 10.1016/j.dsx.2020.06.054. PMID: 32610262.

105. Wang Y, Ao G, Qi X, Zeng J. 2020; Jun. 23. The influence of corticosteroid on patients with COVID-19 infection: a meta-analysis. Am J Emerg Med. [Epub]. DOI:10.1016/j.ajem. 2020.06.040. DOI: 10.1016/j.ajem.2020.06.040. PMID: 32616373. PMCID: PMC7308769.

106. Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. 2019; Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 5:e000935. DOI: 10.1136/rmdopen-2019-000935. PMID: 31245055. PMCID: PMC6560658.

107. Blumentals WA, Arreglado A, Napalkov P, Toovey S. 2012; Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 13:158. DOI: 10.1186/1471-2474-13-158. PMID: 22925480. PMCID: PMC3495205.

108. Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, et al. 2017; BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 56:2257. DOI: 10.1093/rheumatology/kex389. PMID: 29029272. PMCID: PMC6649916.

109. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. 2020; Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21:335–7. DOI: 10.1016/S1470-2045(20)30096-6. PMID: 32066541. PMCID: PMC7159000.

110. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. 2020; Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 31:894–901. DOI: 10.1016/j.annonc.2020.03.296. PMID: 32224151. PMCID: PMC7270947.

111. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. American College of Rheumatology. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68:1–25. DOI: 10.1002/acr.22783. PMID: 26545825.

112. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. 2020; EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 79:700–12. DOI: 10.1136/annrheumdis-2020-217159. PMID: 32434812. PMCID: PMC7286048.

113. Boyman O, Comte D, Spertini F. 2014; Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 10:612–27. DOI: 10.1038/nrrheum.2014.123. PMID: 25112605.

114. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. 2015; Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 386:258–65. DOI: 10.1016/S0140-6736(14)61704-9. PMID: 25975452. PMCID: PMC4580232.

115. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. 2009; Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 301:737–44. DOI: 10.1001/jama.2009.146. PMID: 19224750.

116. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. 2013; Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 309:887–95. DOI: 10.1001/jama.2013.1099. PMID: 23462785. PMCID: PMC3773213.

117. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. 2020; Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 92:814–8. DOI: 10.1002/jmv.25801. PMID: 32253759. PMCID: PMC7262125.

118. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. 2020; Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 31:961–4. DOI: 10.1016/j.annonc.2020.03.300. PMID: 32247642. PMCID: PMC7136869.

119. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. 2020; Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 55:105954. DOI: 10.1016/j.ijantimicag.2020.105954. PMID: 32234467. PMCID: PMC7118634.

120. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. 2020; Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 117:10970–5. DOI: 10.1073/pnas.2005615117. PMID: 32350134. PMCID: PMC7245089.

121. Buonaguro FM, Puzanov I, Ascierto PA. 2020; Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 18:165. DOI: 10.1186/s12967-020-02333-9. PMID: 32290847. PMCID: PMC7154570.

122. Fu B, Xu X, Wei H. 2020; Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 18:164. DOI: 10.1186/s12967-020-02339-3. PMID: 32290839. PMCID: PMC7154566.

123. Nicastri E, Petrosillo N, Ascoli Bartoli T, Lepore L, Mondi A, Palmieri F, et al. 2020; National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 12:8543. DOI: 10.4081/idr.2020.8543. PMID: 32218915. PMCID: PMC7097833.

124. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. 2020; Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 395:e30–1. DOI: 10.1016/S0140-6736(20)30304-4. PMID: 32032529. PMCID: PMC7137985.

125. Richardson PJ, Corbellino M, Stebbing J. 2020; Baricitinib for COVID-19: a suitable treatment? - authors' reply. Lancet Infect Dis. 20:1013–4. DOI: 10.1016/S1473-3099(20)30270-X. PMID: 32251638. PMCID: PMC7270794.

126. Favalli EG, Biggioggero M, Maioli G, Caporali R. 2020; Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 20:1012–3. DOI: 10.1016/S1473-3099(20)30262-0. PMID: 32251639. PMCID: PMC7271155.

127. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. 2020; The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 214:108393. DOI: 10.1016/j.clim.2020.108393. PMID: 32222466. PMCID: PMC7102614.

128. Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. 2020; Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 14:1022. DOI: 10.3332/ecancer.2020.1022. PMID: 32256705. PMCID: PMC7105343.

129. Praveen D, Puvvada RC. M VA. 2020; Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents. 55:105967. DOI: 10.1016/j.ijantimicag.2020.105967. PMID: 32259575.

130. Pawar A, Desai RJ, Gautam N, Kim SC. 2020; Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2:E84–98. DOI: 10.1016/S2665-9913(19)30137-7.

131. Favalli EG. 2020; Tofacitinib's infectious profile: concerns for clinical practice. Lancet Rheumatol. 2:E65–7. DOI: 10.1016/S2665-9913(20)30001-1.

132. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. 1997; A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175–9. DOI: 10.1038/36593. PMID: 9367155.

133. Padigel UM, Kim N, Choi Y, Farrell JP. 2003; TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. J Immunol. 171:5437–41. DOI: 10.4049/jimmunol.171.10.5437. PMID: 14607948.

134. Barbaroux JB, Beleut M, Brisken C, Mueller CG, Groves RW. 2008; Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation. J Immunol. 181:1103–8. DOI: 10.4049/jimmunol.181.2.1103. PMID: 18606662.

135. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al. 2006; Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 12:1372–9. DOI: 10.1038/nm1518. PMID: 17143276.

136. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. FREEDOM Trial. 2009; Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 361:756–65. DOI: 10.1056/NEJMoa0809493. PMID: 19671655.

137. Wensel TM, Iranikhah MM, Wilborn TW. 2011; Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Pharmacotherapy. 31:510–23. DOI: 10.1592/phco.31.5.510. PMID: 21923432.

138. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Amg Bone Loss Study Group. 2008; Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 43:222–9. DOI: 10.1016/j.bone.2008.04.007. PMID: 18539106.

139. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. 2018; Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 33:190–8. DOI: 10.1002/jbmr.3337. PMID: 29105841.

140. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. 2017; Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 32:1291–6. DOI: 10.1002/jbmr.3110. PMID: 28240371.

141. Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry- Rozier B. 2017; Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 102:354–8. DOI: 10.1210/jc.2016-3170. PMID: 27732330.

142. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. 2002; Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46:2287–93. DOI: 10.1002/art.10524. PMID: 12355475.

143. Doaty S, Agrawal H, Bauer E, Furst DE. 2016; Infection and lupus: which causes which? Curr Rheumatol Rep. 18:13. DOI: 10.1007/s11926-016-0561-4. PMID: 26951251.

144. Zandman-Goddard G, Shoenfeld Y. 2005; Infections and SLE. Autoimmunity. 38:473–85. DOI: 10.1080/08916930500285352. PMID: 16373252.

145. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. 2000; T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 97:9203–8. DOI: 10.1073/pnas.97.16.9203. PMID: 10922071. PMCID: PMC16846.

146. Fessler J, Raicht A, Husic R, Ficjan A, Duftner C, Schwinger W, et al. 2016; Premature senescence of T-cell subsets in axial spondyloarthritis. Ann Rheum Dis. 75:748–54. DOI: 10.1136/annrheumdis-2014-206119. PMID: 25688074. PMCID: PMC4819616.

147. Segal BH, Sneller MC. 1997; Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am. 23:219–37. DOI: 10.1016/S0889-857X(05)70327-6. PMID: 9156390.

148. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. 2020; Viral and host factors related to the clinical outcome of COVID-19. Nature. 583:437–40. DOI: 10.1038/s41586-020-2355-0. PMID: 32434211.

149. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. COVID-19 Global Rheumatology Alliance. 2020; Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 79:859–66. DOI: 10.1136/annrheumdis-2020-217871. PMID: 32471903.

150. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. 2020; Factors associated with COVID-19-related death using OpenSAFELY. Nature. 584:430–6. DOI: 10.1038/s41586-020-2521-4. PMID: 32640463.

151. Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, et al. RIER investigators group. 2020; Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 79:1170–3. DOI: 10.1136/annrheumdis-2020-217763. PMID: 32532753. PMCID: PMC7299645.

152. Hasell J. c2020. Testing early, testing late: four countries' approaches to COVID-19 testing compared [Internet]. Our World in Data;Oxford: https://ourworldindata.org/covid-testing-us-uk-korea-italy. cited 2020 May 19.

153. Peck KR. 2020; Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea. Clin Microbiol Infect. 26:805–7. DOI: 10.1016/j.cmi.2020.04.025. PMID: 32344168. PMCID: PMC7182747.

154. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. 2020; Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 395:1973–87. DOI: 10.1016/S0140-6736(20)31142-9. PMID: 32497510. PMCID: PMC7263814.